Close Menu

NEW YORK – Canbridge Pharmaceuticals said on Thursday that it received approval from the Taiwan Food and Drug Administration to market neratinib (Puma Biotechnology's Nerlynx) as an extended adjuvant treatment for adult patients with early-stage, HER2-positive breast cancer after treatment with trastuzumab (Genentech's Herceptin).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.